Search Results
Mar 19, 2026, 14:20 ET Stamus Networks kündigt Suricata Language Server 2.0 mit KI-Agentenfunktionen und Unterstützung für Continuous Integration an
Suricata-Regeln.SLS 2.0 schließt diese Lücke mit einer GitHub Action, die Signaturen innerhalb von Repositories überprüft, automatisierte Qualitätskontrollen in CI/CD-Pipelines ermöglicht und dafür sorgt, dass Builds bei Syntaxfehlern oder Warnungen fehlschlagen können.SID-Erkennung im gesamten WorkspaceSLS
More news about: Stamus Networks
Mar 19, 2026, 10:34 ET Stamus Networks anuncia Suricata Language Server 2.0
Acción de GitHub que verifica las firmas dentro de los repositorios, lo que permite realizar comprobaciones de calidad automatizadas en los flujos de CI/CD y permite que las compilaciones fallen ante errores de sintaxis o advertencias.Detección de SID en todo el espacio de trabajoSLS
More news about: Stamus Networks
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
hematologic malignancies program, including the completion of enrollment in Cohort C of the Phase 1 ALLOHA trial and FDA clearance of INDs for two new CD45-targeting candidates, TSC-102-A01 and TSC-102-A03. Full year 2025 collaboration and license revenue reached $10.3 million versus $2.8 million in 2024,
More news about: USA News Group
Mar 19, 2026, 09:00 ET Boost Security Launches Developer Endpoint Security to Secure AI-Driven Software Development at the Source
infrastructure, is secured at every stage. Boost Security helps us get there, with controls natively built into engineering workflows through source control and CI/CD pipelines in a single comprehensive platform."The platform secures the full AI development workflow, from the moment a prompt is sent to a coding
More news about: Boost Security
Mar 19, 2026, 09:00 ET Aikido Receives the 2026 Global Application Security Posture Management Customer Value Leadership Recognition for Excellence in Developer-First Security Innovation
replacing fragmented tools with a single, cost-effective solution. By embedding automated checks early in integrated development environments (IDE) and CI/CD pipelines, Aikido reduces operational friction and accelerates remediation. The platform's AI-powered capabilities support autonomous discovery of risk
More news about: Frost & Sullivan
Mar 19, 2026, 09:00 ET Aikido Receives the 2026 Global Application Security Posture Management Customer Value Leadership Recognition for Excellence in Developer-First Security Innovation
replacing fragmented tools with a single, cost-effective solution. By embedding automated checks early in integrated development environments (IDE) and CI/CD pipelines, Aikido reduces operational friction and accelerates remediation. The platform's AI-powered capabilities support autonomous discovery of risk
More news about: Frost & Sullivan
Mar 19, 2026, 09:00 ET Panther Launches the Complete AI SOC Platform, Closing the Loop on Security Operations
production-ready Python detections, delivered as GitHub pull requests with human review required before deployment. Output is real code in a real CI/CD pipeline.Proactive Threat Coverage: Scheduled AI runs analyze telemetry across the full data lake to surface threats beyond what pre-written
More news about: Panther
Mar 19, 2026, 07:00 ET CD&R Expands Climate Leadership Program to Europe with Imperial College Business School and Extends Columbia University Partnership in the U.S. for Second Year
2026 /PRNewswire/ -- CD&R (the "Firm") today announced the expansion of its Climate Leadership Program to Europe through a new partnership with Imperial College Business School's Leonardo Centre on Business for Society. The program will serve senior executives from CD&R's portfolio companies and
More news about: CD&R
Mar 19, 2026, 07:00 ET CD&R Expands Climate Leadership Program to Europe with Imperial College Business School and Extends Columbia University Partnership in the U.S. for Second Year
2026 /PRNewswire/ -- CD&R (the "Firm") today announced the expansion of its Climate Leadership Program to Europe through a new partnership with Imperial College Business School's Leonardo Centre on Business for Society. The program will serve senior executives from CD&R's portfolio companies and
More news about: CD&R
Mar 19, 2026, 04:00 ET Stamus Networks Announces Suricata Language Server 2.0 with AI Agent Skills and Continuous Integration Support
production.SLS 2.0 addresses this gap with a GitHub Action that verifies signatures within repositories, enabling automated quality checks in CI/CD pipelines and allowing builds to fail on syntax errors or warnings.Workspace-Wide SID AwarenessSLS 2.0 now tracks Signature IDs
More news about: Stamus Networks
Mar 18, 2026, 09:14 ET Phanes Therapeutics to Present Three Clinical Posters at AACR 2026
University of Texas MD Anderson Cancer CenterTitle: Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept studyDate/Time: 4/20/2026 | 2:00-5:00 PM PSTLocation: Poster
More news about: Phanes Therapeutics, Inc.
Mar 18, 2026, 08:51 ET 晶泰AI賦能管線再迎臨床轉化：萊芒生物「千分之一」劑量CAR-T療法獲FDA臨床批准
2026年3月18日 /美通社/ -- 近日，晶泰科技孵化企業萊芒生物宣佈，其研發的 META 10-19 注射液（代謝增強型 CD19 CAR-T）的新藥臨床試驗申請（IND）已獲得美國食品藥品監督管理局（FDA）批准，計劃最早於今年第四季度開啟臨床試驗。本次獲批適應症為復發或難治性 CD19 陽性的 B 細胞血液腫瘤，包括 B 細胞急性淋巴細胞白血病（B-ALL）與 B 細胞非霍奇金淋巴瘤（B-NHL）的多種常見亞型。
More news about: 晶泰科技
Mar 18, 2026, 08:22 ET Annual General Meeting in Alfa Laval AB (publ)
https://mb.cision.com/Public/905/4322913/8f9ba19cd9a868aa.pdfNotice to attend
More news about: Alfa Laval
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
NCT071196748) in moderately-to-severely active ulcerative colitis; and ICONIC-CD (
More news about: Johnson & Johnson
Mar 18, 2026, 07:01 ET Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis
therapies, today announced that dosing is underway for the first cohort of patients in its Phase 1a clinical trial evaluating KT501. KT501 is a first-in-class CD19xBCMAxCD3 trispecific T-cell engager (TCE). The study is being conducted in adult patients with Rheumatoid Arthritis (RA).
More news about: Kali Therapeutics
Mar 18, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
cytotoxic markers were analyzed using flow cytometry. In vitro studies evaluated NK cell cytotoxic function following Quar Oze treatment by measuring CD107a degranulation and CellTrace Violet–based proliferation. In the therapeutic treatment group, 67% of Tusc2 KO mice and 33% of Tusc2 WT mice achieved
More news about: Genprex, Inc.
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancers and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple
More news about: Antengene Corporation Limited
Mar 17, 2026, 19:00 ET Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 - at AACR Annual Meeting 2026
40Poster Board Number: 11Poster Number: 5193Title: Novel SynKIR™-310 outperforms CD3-based second-generation CD28 or 41BB co-stimulated CAR T in B cell non-Hodgkin lymphoma xenograft mice and shows early clinical signalPresenting
More news about: Verismo Therapeutics
Mar 17, 2026, 16:30 ET Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting
PTAbout IMT-009 IMT-009 is a fully human, Fc-attenuated IgG1 monoclonal antibody that binds to CD161 and blocks its interaction with its ligand, CLEC2D. Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity. IMT-009 is under evaluation in a Phase
More news about: Immunitas Therapeutics, Inc.
Mar 17, 2026, 09:02 ET Opsera Unified Insights Now Available in the Microsoft Marketplace
moving from traditional SDLC to an AI-driven software delivery lifecycle (AI-SDLC), and Opsera empowers this transformation by automating complex CI/CD workflows, enforcing security and compliance, and providing actionable insights across every stage of development. By integrating with the Microsoft
More news about: Opsera
Mar 17, 2026, 08:29 ET ActiveState Launches Curated Catalogs to Neutralize Security Risks in AI-Generated Code
Integration with Artifact Repositories: Packages are delivered in native formats, such as Python Wheels, and are compatible with existing tools and CI/CD pipelines. The Curated Catalog works seamlessly with popular artifact managers, including JFrog Artifactory, Sonatype Nexus, Cloudsmith, GitHub Packages,
More news about: ActiveState
Mar 17, 2026, 08:07 ET Beurer Expands U.S. Access to German-Engineered, Clinically Supported Drug-Free Pain Relief Solutions
https://www.cochrane.org/evidence/CD011890_transcutaneous-electrical-nerve-stimulation-tens-chronic-pain-overview-cochrane-reviewsHeat therapy has also demonstrated functional improvement benefits in peer-reviewed
More news about: Beurer North America
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia submissão regulatória suplementar de MINJUVI® (tafasitamabe) para linfoma folicular na Argentina e no México
pacientes."Sobre o MINJUVI® (tafasitamabe)MINJUVI® (tafasitamabe) é um anticorpo monoclonal aprimorado com Fc citolítico que tem como alvo o CD19. O tafasitamabe incorpora um domínio Fc projetado pela XmAb® que faz a mediação da lise das células B por meio da apoptose e do mecanismo
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la presentación regulatoria complementaria de MINJUVI® (tafasitamab) para linfoma folicular en Argentina y México
(tafasitamab)MINJUVI® (tafasitamab) es un anticuerpo monoclonal citolítico humanizado con modificaciones en la región Fc dirigido a CD19. Tafasitamab incorpora un dominio Fc de ingeniería XmAb®, que media la lisis de células B a través de la apoptosis y mecanismos efectores
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics Anuncia Aprovação de Indicação Adicional para MINJUVI® (tafasitamabe) no Brasil
(TACT). Sobre o MINJUVI® (tafasitamabe)MINJUVI® (tafasitamabe) é um anticorpo monoclonal aprimorado com Fc citolítico que tem como alvo o CD19. O tafasitamabe incorpora um domínio Fc projetado pela XmAb® que faz a mediação da lise das células B por meio da apoptose e do mecanismo
More news about: Knight Therapeutics Inc.